针对Keap1/Nrf2作为心肌梗塞治疗药物的蛋白质类聚合物
Joshua M Mesfin1, Kendal P Carrow2, Alexander Chen3
1Shu Chien-Gene Lay Department of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California San Diego, La Jolla, CA, 92037, USA.
Advanced materials (Deerfield Beach, Fla.)
|April 25, 2025
概括
一种针对Keap1/Nrf2相互作用的新型蛋白样聚合物 (PLP) 疗法在治疗心肌梗塞 (MI) 方面表现有前途. 这种创新方法可以减轻氧化应激和炎症,改善心脏功能后MI.
科学领域:
- 生物化学 生化学
- 心血管医学 心血管医学
- 药物发现 药物发现 药物发现
背景情况:
- 心肌梗塞 (MI) 引起氧化应激和炎症,往往导致心力衰竭 (HF).
- 目前的治疗方法在预防心脏中风后不良心脏改造方面缺乏有效性.
- 针对Keap1/Nrf2通路提供了一种潜在的治疗策略,以对抗MI引起的损伤.
研究的目的:
- 开发和评估一种新型的Nrf2-模拟蛋白样聚合物 (PLP) 作为心肌梗塞 (MI) 的治疗剂.
- 调查Keap1抑制PLPs (Keap1i-PLPs) 减轻MI后的氧化应激和炎症的能力.
- 评估Keap1i-PLPs在改善心脏功能和预防心脏病发作后不良改造方面的 in vivo 疗效.
主要方法:
- 使用一种类似蛋白质的聚合物 (PLP) 平台,旨在模仿Nrf2并抑制Keap1-Nrf2相互作用.
- 使用初级心肌细胞进行了体外测定,以评估细胞保护和Nrf2激活.
- 在MI的老鼠模型中进行了体内研究,静脉注射Keap1i-PLPs以评估心脏功能和潜在机制.
主要成果:
- Keap1i-PLPs通过Nrf2激活在亚纳米度下,在心肌细胞中表现出强大的细胞保护作用,对抗氧化应激.
- 单次静脉注射Keap1i-PLPs剂量显著改善了MI后大鼠的心脏功能.
- 治疗效益归因于免疫调节,抗亡和血管新生机制.
结论:
- Keap1i-PLPs有效地破坏了Keap1-Nrf2蛋白质与蛋白质的相互作用,在全身使用后.
- 这种新的治疗策略显示出治疗心肌梗塞和其他与氧化压力相关的疾病的巨大潜力.
- PLP平台为开发针对细胞内蛋白质与蛋白质相互作用的治疗方法提供了一个有前途的方法.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
01:46Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K